enGene
ENGN | NASDAQ
$1.72
-$0.17 (-8.99%)
At close: Nov 17, 2026, 4:00 PM ET
$1.87
+$0.15 (+8.70%)
After-hours:
Nov 17, 2026, 7:47 PM ET
-8.99%
(1D)Rating
29.5
+1.5 ptsFundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #798/1014 (Top 79%)
Key Statistics
Market Data
Market Cap $115.27M
1D Range
1.68 1.94
52W Range
1.44 12.17
Valuation (TTM)
PE -6.14
PB 0.50
EV/EBITDA 0.89
Valuation (NTM)
Forward PE N/A
Forward PEG N/A
Price Target $4.00
Cash Flow
FCF Yield -90.2%
SBC Adj. FCF Yield -105.3%
SBC Impact -16.7%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 88.3% |
-21.2%
FCF 3Y | 5Y -43.1% |
-48.0%
Returns
ROA -1.7%
ROE -2.1%
ROIC -1.6%
Financial Health
Net Cash
$238.72M
Current Ratio 10.21
Interest Coverage -1.53
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by adminis...
Sector Healthcare
Industry Biotechnology
Employees 82
IPO Date Feb 1, 2022
Website www.engene.com
Fiscal Year November - October
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
8
Consensus
Hold
Price Target
$4.00
Upside
+132.56%
Buy (4)
Hold (3)
Sell (1)
Add to Watchlist
Select watchlists to add or remove ENGN